ArticleBMC geriatrics2026
Platelet reactivity in polymorbid older patients and the effect of 4-methylcatechol.
Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundOlder patients often suffer from multiple disorders and are hence frequently burdened by polypharmacy. Prevention of cardiovascular events using antiplatelet drugs might be indicated among older populations, but there are no studies assessing platelet function in these patients.
methodsUsing impedance aggregometry, we compared platelet reactivity to 7 aggregation inducers between a group of 44 polymorbid older patients aged 78 + years (PP), and 50 generally healthy younger controls (median age, 44 years). None of the subjects were treated with antiplatelet therapy. We also examined their response to antiplatelet drugs (acetylsalicylic acid, ticagrelor, vorapaxar) and an experimental compound, 4-methylcatechol, a small polyphenol metabolite of many natural polyphenolic compounds. Data analysis was performed in the whole group as well as after removing or splitting the groups based on concomitantly administered drugs. Linear mixed-effects modelling was used to investigate the impact of both drugs and comorbidities on the obtained results.
resultsA clinically achievable concentration of ASA (30 µM) failed to block platelet aggregation when arachidonic acid was used as an inducer, but the response to ticagrelor, vorapaxar, and 4-methylcatechol with relevant inducers was significant. However, the sensitivity to ticagrelor and vorapaxar was lower in PP when compared to healthy controls. The analysis also confirmed similar activity for 4-methylcatechol, but lower activity for acetylsalicylic acid in our PP. Further analyses excluding specific drugs did not significantly alter these outcomes. Inflammatory markers and the presence of type 2 diabetes mellitus were significant predictors of platelet reactivity while basic blood parameter data had no clear impact.
conclusionsThe ex vivo response of platelets from PP to the standard antiplatelet drugs was lower. In contrast, they responded well to 4-methylcatechol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.